Abstract:More than 80% of patients with advanced ovarian cancer need second-line chemotherapy for the recurrence. A number of large scale randomized controlled trials have confirmed that the platinum -based co...More than 80% of patients with advanced ovarian cancer need second-line chemotherapy for the recurrence. A number of large scale randomized controlled trials have confirmed that the platinum -based combination chemotherapy,such as paclitaxel combined with carboplatin or gemcitabine combined with carboplatin,can be used as the best options for its superiorities on effectiveness and survival improvement in platinum-sensitive patients compared with platinum monotherapy. However,the effects of any kinds of chemotherapy are not satisfactory in these platinum-resistant patients,and single-agent chemotherapy is commonly used as palliative therapy in clinic for its fewer adverse effects and convenient administration. More randomized controlled trials are needed to prove the value of combination chemotherapy.Read More
Publication Year: 2009
Publication Date: 2009-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot